Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02382016 · ClinicalTrials.gov registry record · Phase 4

PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial

A Phase 4 study, sponsored by Actelion.

Completed
Registry status
Phase 4
Development phase
85
Enrollment target

NCT02382016 is a Phase 4 study that has completed, run by Actelion. The registered enrollment target is 85 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02382016, a Phase 4 study, has completed, sponsored by Actelion.

COMPLETED
Registry status
Phase 4
Development phase
85 participants
Enrollment target

Study Summary

24-week study to evaluate the efficacy and safety of macitentan for the treatment of portopulmonary hypertension.

Interventions

  • OTHER Placebo
  • DRUG Macitentan

Trial Details

FieldValue
Enrollment Target 85 participants
Start Date 2015-06-23
Est. Completion 2018-10-31
Phase Phase 4

Sponsor

Actelion

63 total trials

What the Registry Record Tells You About NCT02382016

The ClinicalTrials.gov registry entry for NCT02382016 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT02382016 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02382016 about?

NCT02382016 is a clinical study titled "PORtopulmonary Hypertension Treatment wIth maCitentan - a randOmized Clinical Trial". 24-week study to evaluate the efficacy and safety of macitentan for the treatment of portopulmonary hypertension.

What is the current status of trial NCT02382016?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 85 participants. The study started on 2015-06-23. Estimated completion is 2018-10-31.

What interventions are being tested in trial NCT02382016?

The interventions under investigation include: Placebo (OTHER), Macitentan (DRUG).

Who is sponsoring clinical trial NCT02382016?

This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.